# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

#### OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

|                      |                             |                          | of Section So(n) of the investment Company Act of 1940  |                        |  |                       |  |  |
|----------------------|-----------------------------|--------------------------|---|------------------------|--|-----------------------|--|--|
| 1. Name and Ad       | ddress of Reporting K BRUCE | Person*                  | 2. Issuer Name and Ticker or Trading Symbol<br><u>DISCOVERY LABORATORIES INC /DE/</u><br>[ DSCO ] |                        | elationship of Reporting Person(s) to Issuer<br>eck all applicable)<br>X Director 10% Owner  |                       |  |  |
| (Last)<br>2600 KELLY | (First)<br>Y ROAD           | (Middle)                 | 3. Date of Earliest Transaction (Month/Day/Year)<br>06/11/2013                                    |                        | Officer (give title below)   | Other (specify below) |  |  |
| (Street)<br>WARRINGT |                             | 18976                    | 4. If Amendment, Date of Original Filed (Month/Day/Year)  | 6. Indiv<br>Line)<br>X | ividual or Joint/Group Filing (Check Applicab<br>Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person |                       |  |  |
| (City)               | (State)                     | (Zip)<br>Table I - Non-E | Derivative Securities Acquired, Disposed of, or Benef   | icially                | Owned  |                       |  |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code (Instr.<br>8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and<br>5) |               |                   | Securities<br>Beneficially         | (D) or Indirect<br>(I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership |
|---------------------------------|--|---|---|---|---|---------------|-------------------|------------------------------------|-----------------------------------|---|
|                                 |  |   | Code                                    | v | Amount  | (A) or<br>(D) | Price             | Transaction(s)<br>(Instr. 3 and 4) |                                   | (Instr. 4)  |
| Common Stock <sup>(1)</sup>     | 06/11/2013                                 |   | A                                       |   | 4,734   | Α             | \$ <mark>0</mark> | 4,734                              | D                                 |   |

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)       | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | n of   |     | 6. Date Exerci<br>Expiration Da<br>(Month/Day/Ye | te                 | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|--------|-----|--|--------------------|---|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A)    | (D) | Date<br>Exercisable                              | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy) | \$1.69  | 06/11/2013                                 |   | A                            |   | 15,000 |     | 06/11/2014 <sup>(2)</sup>                        | 06/11/2023         | Common<br>Stock   | 15,000                                 | \$0   | 15,000   | D  |  |

**Explanation of Responses:** 

1. Restricted Stock Unit shall fully vest upon the first anniversary of the date of grant.

2. Stock Option shall fully vest upon the first anniversary of the date of grant.

**Remarks:** 

#### /s/ Mary B. Templeton, Esq., as 06/13/2013

Attorney in fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## LIMITED POWER OF ATTORNEY

# FOR SECTION 16(a) REPORTING

KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints David Lopez, Mary B. Templeton and John Tattory, and each of them, as the undersigned's true lawful attorney-in-fact (the "<u>Attorney-in-Fact</u>"), with full power of substitution and re-substitution, each with power to act alone for the undersigned and in the undersigned's name, place and stead, in any and all capacities to:

1. Prepare, execute and file for an on behalf of the undersigned, in the undersigned's capacity as the officer, director or 10% or greater shareholder of Discovery Laboratories Inc. (the "<u>Company</u>"), with the Securities and Exchange Commission and any national securities exchange or securities quotation system, any and all reports (including any amendment thereto) of the undersigned required or considered advisable under Section 16(a) of the Securities Exchange Act of 1934 (the "<u>Exchange Act</u>") and the rules and regulations thereunder, with respect to the equity securities of the Company, including Forms 3, 4, and 5; and

2. Obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's equity securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:

1. This Limited Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act at his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information;

2. Any document prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable;

3. Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 16 of the Exchange Act, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and

4. This Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 16 of the Exchange Act, including, without, limitation, the reporting requirements under Section 16(a) of the Exchange Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and preform each and every act and thing requisite, necessary or convenient to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Limited Power of Attorney.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, or 5 with respect to the undersigned's transactions in equity securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.

This Limited Power of Attorney shall be governed and construed in accordance the laws of the State of Pennsylvania without regard to conflict-of-law principles.

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of September 15, 2010.

/s/ Bruce Peacock Bruce Peacock